Las Glucogenosis en España: Situación Actual y Guías Informativas

Muscle and Nerve; 38 (3): 1211-1212.

[26] Slonim AE et al ( 1983) "Improvement of muscle function in acid maltase de-

ficiency by high-protein therapy", Neurology; 33: 34-38.

[27] Umpleby AM et al (1989) "The effect of a high protein diet on leucine and

alanine turnover in acid maltase deficiency", Journal of Neurology, Neurosurgery
and Psychiatry; 52: 954-961.

[28] Bodamer OA et al ( 1997) "Dietary treatment in late-onset acid maltase defi-

ciency", European Journal of Pediatrics; 156 Suppl 1: 39-42.

[29| Selak MA et al (1999) "Mitochondrial activity in Pompe 's disease", Pediatric

Neurology; 23 ( 1 ): 54-57.

[30] Bodamer OA et al (2000) "The effects of 1-alanine supplementation in late-

onset glycogen storage disease type II", Neurology; 55: 710-712.

[31] Bodamer OA et al (2002) "L-alanine supplementation in late infantile glyco-

gen storage disease type II", Pediatric Neurology; 27 (2): 145-146.

[32] Hanna R et al (2007) "Fractures in children with Pompe disease: a potential

long-term complication", Pediatrie Radiology; 37 (5): 437-445.

133] Khan A et al (2007) "Osteopenia, increased risk and improvement in bone

density with the use of Bisphosphonates in patients with Pompe disease", Bone;
40(6, 1 ): S54.

[34] Martiniuk F et al (2000) "Correction of glycogen storage disease type II by

enzyme replacement with a recombinant human acid maltase produced by over-
expression in a CHO-DHFR(neg) cell line", Biochemical and Biophysical Re-
search Communications; 276 (3): 917-923.

[35] Van den Hout H et al (2000) "Recombinant human alpha-glucosidase from

rabbit milk in Pompe patients". Lancet; 356: 397-398.

[36] Van den Hout H et al (2000) "First clinical test with recombinant human

alpha-glucosidase from rabbit milk shows therapeutic effect in Pompe patients",
American Journal of Human Genetics; 67: supplement to volume 67, 10.

155

Las Glucogenosis en España

(37] Van den Hout JM et al (2001) "Enzyme therapy for Pompe disease with re-

combinant human glucosidase from rabbit milk", Journal of Inherited Metabolic
Diseases; 24: 266 -274.

[38] Amalfitano A et al (2001) "Recombinant human acid-a-glucosidase enzyme

therapy for infantile glycogen storage disease type II: results of a phase I/I I clin-
ical trial", Genetics in Medicine; 3: 132-138.

[39] Klinge L et al (2002) "Safety and efficacy of recombinant acid alpha-glu-

cosidase (rhGAA) in patients with classical infantile Pompe disease", Proceedings
of the 2002 European Society of Human Genetics Conference.

[40] Kishnani P et al (2002) "Treatment of Classical Infantile Pompe Disease

(CIPD) with recombinant human acid alpha glucosidase (rhgaa): preliminary six
month data from a phase 2 study", Proceedings ot the 2002 American Society of
Human Genetics Annual Meeting.

[41] Kishnani P et al (2003) "Enzyme replacement therapy with recombinant

human acid alpha glucosidase in infantile Pompe disease: Duke experience", Pro-
ceedings of the 2003 International Pompe Conference.

[42] Winkel LP et al (2003) "Morphological changes in muscle tissue of patients

with infantile Pompe's disease receiving enzyme replacement therapy". Muscle
and Nerve ; 27 (6): 743-751.

[43] Winkel LP et al (2004) "Enzyme replacement therapy in late-onset Pompe's

disease: A three-year follow-up", Annals of Neurology; 55 (4): 495-502.

[44] Kishnani P et al (2004) "Enzyme Replacement Therapy (ERT) for infantile

onset Pompe disease: Long term follow-up results", Proceedings of the 2004 An-
nual Symposium on Lysosomal Storage Disorders.

[45] Van den Hout JM et al (2004) "Long-term intravenous treatment of Pompe

disease with recombinant human -glucosidase from milk", Pediatrics; 113 (5):
448-457.

[46] Klinge L et al (2005) "Enzyme replacement therapy in classical infantile

Pompe disease: results of a ten-month follow-up study", Neuropediatrics; 36 ( 1 ):
6-11.

156

Las Glucogenosis en España

[47] Klinge L et al (2005) "Safety and efficacy of recombinant acid alpha-glu-

cosidase (rhGAA) in patients with classical infantile Pompe disease: results of a
phase II clinical trial", euromuscular Disorders; 15 (1): 24-31.

[48] Van der Beek NA et al (2005) "Pompe disease (glycogen storage disease type

II): clinical features and enzyme replacement therapy", Acto Neurologica Belgica;
106 (2): 82-86.

[49] Thurberg BLet al (2006) "Characterization of pre- and post-treatment pathol-

ogy after enzyme replacement therapy for Pompe disease", Laboratory Investi-
gation; 86 (12): 1208-1220.

[50] Kishnani PS et al (2007) "Recombinant human acid [alpha]-glucosidase:

major clinical benefits in infantile-onset Pompe disease", Neurology; 68 (2): 99-
109.

[51] Wagner KR (2007) "Enzyme replacement for infantile Pompe disease: the

first step toward a cure", Neurology; 68 (2): 88-89.

[52] Rossi, M et al (2007) "Long-term enzyme replacement therapy for Pompe dis-

ease with recombinant human alpha-glucosidase derived from Chinese hamster
ovary cells". Journal of Child Neurology; 22 (5): 565-573.

[53] Ravaglia S et al (2008) "Enzyme replacement therapy in severe adult-onset

glycogen storage disease type II", Advances in Therapy; 25 (8): 820-829.

[54| Case LE et al (2008) "Improvement with ongoing enzyme replacement ther-

apy in advance late-onset Pompe disease: a case study", Molecular Genetics and
Metabolism; 95 (4): 233-235.

[551 Hamdan MA et al (2008) "Early administration of enzyme replacement ther-

apy for Pompe disease: short-term follow-up results", Journal of Inherited Meta-
bolic Diseases; en prensa.

[56] Merk T et al (2009) "Glycogen storage disease type II (Pompe disease) - in-

fluence of enzyme replacement therapy in adults", European Journal of Neurol-
ogy; en prensa.

[57| Levine JC et al (2008) "Cardiac remodeling after enzyme replacement ther-

apy with acid alpha-glucosidase for infants with Pompe disase", Pediatric Cardi-
ology; 29 (6): 1033-1042.

157

Las Glucogenosis en España

|58| Huang PK et al (2008) "Torsade de pointes ventricular tachycardia during

elective intubation in a patient with Pompe disase", Paediatric Anaesthesia; 18
(4): 346-348.

(59] McDowell R et al (2008) "Arrhythmias in patients receiving enzyme re-

placement therapy for infantile Pompe disease", Genetics in Medicine; 10 (10):

758-762.

[60] Raben N et al (2005) "Replacing acid alpha-glucosidase in Pompe disease:
recombinant and transgenic enzymes are equipotent, but neither completely clears
glycogen from type II muscle fibers", Molecular Therapy, 11 (1): 48-56.

[61] MoVie-Wylie JC et al (2008) "Biochemical and pharmacological character-

ization of different recombinant acid alpha-glucosidase preparations for the treat-
ment of Pompe disease". Molecular Genetics and Metabolism; 94 (4): 448-455.

[62] Fukuda T et al (2006) "Autophagy and mistargeting of therapeutic enzyme in

skeletal muscle in Pompe disease", Molecular Therapy; 14 (6): 831-839.

|63] Fukuda T et al (2006) "Autophagy and lysosomes in Pompe disease", Au-

tophagy: 2 (4): 318-320.

[64] Fukuda T et al (2006) "Dysfunction of endocytic and autophagic pathways

in a lysosomal storage disease", Annals of Neurology; 59 (4): 700-708.

[65] Malicdan MC et al (2008) "Lysosomal myopathies: an excessive build-up in

autophagosomes is too much to handle", Neuromuscular Disorders; 18 (7): 521-

529.

[66] Raben N et al (2008) "Supression of autophagy in skeletal muscle uncovers
the accumulation of ubiquitinated proteins and their potential role in muscle dam-
age in Pompe disease". Human Molecular Genetics; 17 (24): 3897-3908.

[67 ] Raben N et al (2009) "When more is less: excess and deficiency of autophagy

coexist in skeletal muscle in Pompe disease", Autophagy; 5(1): 111-113.

[68] Cerini E et al (2007) "Pompe's disease: the role of early diagnosis and treat-

ment". Pediatria Medica e Chirurgica; 29 (5): 270- 272.

169] Hawes ML et al (2007) "Differential muscular glycogen clearance after en-

zyme replacement therapy in a mouse model of Pompe disease", Molecular Ge-
netics and Metabolism; 91 (4): 343-351.

158

Las Glucogenosis en España

[70] Sun B et al (2007) "Enhanced response to enzyme replacement therapy in

Pompe disease: after the induction of immune tolerance", American Journal of
Human Genetics; 81 (5): 1042- 1049.

[71] Joseph A et al (2008) "Immune tolerance induction to enzyme-replacement

therapy by co-administration of short-term, low-dose methotrexate in a murine
Pompe disease model", Clinical and Experimental Immunology; 152 (1): 138-
146.

[72] Mendelsohn NJ et al (2009) "Elimination of antibodies to recombinant en-

zyme in Pompe"s disease", New England Journal of Medicine; 360 (2): 194- 195.

[73] Zhu Y et al (2005) "Carbohydrate-remodelled acid alpha-glucosidase with

higher affinity for the cation-independent mannose 6-phosphate receptor demon-
strates improved delivery to muscles of Pompe mice", Biochemical Journal; 389
(3): 619-628.

[74] Cardone M et al (2008) "Abnormal mannose-6-phosphate receptor traffick-

ing impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts",